文献速递前列腺癌

挽救性根治性前列腺切除术后持续性PSA的影响:一项多中心研究

Impact of persistent PSA after salvage radical prostatectomy: a multicenter study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2023-10-06

该多中心研究纳入2000至2021年间12个中心因前列腺癌复发接受挽救性根治性前列腺切除术的580例患者,42%(n=242)术后首次PSA≥0.1 ng/ml即持续性PSA。中位随访38个月,持续性PSA组84个月无生化复发生存6.6% vs 59%、无转移生存71% vs 88%、总生存77% vs 94%(均p<0.01);多因素Cox模型中持续性PSA是生化复发(HR 5.47,p<0.001)和死亡(HR 3.07,p<0.01)的独立预测因子。

要点

  • 挽救性根治性前列腺切除术后42%(242/580)患者存在持续性PSA(≥0.1 ng/ml)。
  • 持续性PSA组84个月无生化复发生存6.6% vs 59%,无转移生存71% vs 88%,总生存77% vs 94%(均p<0.01)。
  • 持续性PSA是生化复发(HR 5.47,p<0.001)和死亡(HR 3.07,p<0.01)的独立预测因子。

核心结论

  • 挽救性根治性前列腺切除术后持续性PSA常见,且是更差肿瘤学结局的独立预测因子。
  • 作者建议接受挽救性根治性前列腺切除术的患者术后应密切监测以识别持续性PSA者。

研究设计与样本

  • 多中心研究,从12个高容量中心识别2000至2021年间因复发性前列腺癌接受挽救性根治性前列腺切除术的患者。
  • 仅纳入挽救性根治性前列腺切除术后有可用PSA的患者,共580例。
  • 采用Kaplan-Meier分析和多因素Cox回归模型检验持续性PSA对生化复发、转移和任何死亡的影响。
  • 持续性PSA定义为挽救性根治性前列腺切除术后首次PSA测量值≥0.1 ng/ml。

主要发现

  • 580例患者中42%(n=242)存在持续性PSA。
  • 挽救性根治性前列腺切除术后中位随访38个月,中位至挽救性根治性前列腺切除术时间64个月,中位至术后首次PSA时间2.2个月。
  • 术后84个月,持续性PSA组 vs 不可测PSA组的无生化复发生存为6.6% vs 59%,无转移生存为71% vs 88%,总生存为77% vs 94%(均p<0.01)。
  • 多因素Cox模型中,持续性PSA是生化复发的独立预测因子(HR 5.47,p<0.001)。
  • 多因素Cox模型中,持续性PSA是死亡的独立预测因子(HR 3.07,p<0.01)。

临床怎么用

  • 作者建议接受挽救性根治性前列腺切除术的患者术后应密切监测,以识别持续性PSA者。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Persistent prostatic specific antigen (PSA) represents a poor prognostic factor for recurrence after radical prostatectomy (RP). However, the impact of persistent PSA on oncologic outcomes in patients undergoing salvage RP is unknown. To investigate the impact of persistent PSA after salvage RP on long-term oncologic outcomes. MATERIAL AND METHODS: Patients who underwent salvage RP for recurrent prostate cancer between 2000 and 2021 were identified from twelve high-volume centers. Only patients with available PSA after salvage RP were included. Kaplan-Meier analyses and multivariable Cox regression models were used to test the effect of persistent PSA on biochemical recurrence (BCR), metastasis and any death after salvage RP. Persistent PSA was defined as a PSA-value ≥ 0.1 ng/ml, at first PSA-measurement after salvage RP. RESULTS: Overall, 580 patients were identified. Of those, 42% (n = 242) harbored persistent PSA. Median follow-up after salvage RP was 38 months, median time to salvage RP was 64 months and median time to first PSA after salvage RP was 2.2 months. At 84 months after salvage RP, BCR-free, metastasis-free, and overall survival was 6.6 vs. 59%, 71 vs. 88% and 77 vs. 94% for patients with persistent vs. undetectable PSA after salvage RP (all p < 0.01). In multivariable Cox models persistent PSA was an independent predictor for BCR (HR: 5.47, p < 0.001) and death (HR: 3.07, p < 0.01). CONCLUSION: Persistent PSA is common after salvage RP and represents an independent predictor for worse oncologic outcomes. Patients undergoing salvage RP should be closely monitored after surgery to identify those with persistent PSA.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Preisser F, Incesu RB, Rajwa P, et al. Impact of persistent PSA after salvage radical prostatectomy: a multicenter study. Prostate Cancer Prostatic Dis. 2023. PMID: 37803241. doi:10.1038/s41391-023-00728-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。